Author details

Full Name

Kristopher R Bosse

Affiliation

ORCID

Career Start Year

2009

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37688570	BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.	J Natl Cancer Inst	2024
37688579	Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.	J Natl Cancer Inst	2024
36747619	Germline pathogenic variants in 786 neuroblastoma patients.	medRxiv	2023
37938771	Targeting of intracellular oncoproteins with peptide-centric CARs.	Nature	2023
37611092	A MYCN-independent mechanism mediating secretome reprogramming and metastasis in <i>MYCN</i>-amplified neuroblastoma.	Sci Adv	2023
36778420	<i>BARD1</i> germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.	bioRxiv	2023
34971569	GPC2-CAR TÂ cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.	Cancer Cell	2022
36108156	Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.	Cancer Discov	2022
36167467	Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.	J Immunother Cancer	2022
36460335	GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.	J Immunother Cancer	2022
34732890	Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.	Nature	2021
34337560	A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.	Cell Rep Med	2021
32897422	Correction to: Genetic susceptibility to neuroblastoma: current knowledge and future directions.	Cell Tissue Res	2021
34465595	Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.	Molecular Cancer Therapeutics	2021
34113750	Immune-Based Approaches for the Treatment of Pediatric Malignancies.	Annu Rev Cancer Biol	2020
32339949	LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase.	Neoplasia	2020
32211329	CAMKV Is a Candidate Immunotherapeutic Target in <i>MYCN</i> Amplified Neuroblastoma.	Front Oncol	2020
29589100	Genetic susceptibility to neuroblastoma: current knowledge and future directions.	Cell Tissue Res	2018
28898695	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.	Cancer Cell	2017
26539795	Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.	Cancer	2016
26910291	Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.	MAbs	2016
26325556	Improving Patient Outcomes With Cancer Genomics: Unique Opportunities and Challenges in Pediatric Oncology.	JAMA	2015
25582817	A rapid progression of disease after surgical excision of a malignant rhabdoid tumor of the bladder.	Urology	2015
25950873	Suspected posaconazole toxicity in a pediatric oncology patient.	Pediatric Blood and Cancer	2015
25018128	Malignant rhabdoid tumor of the bladder and ganglioglioma in a 14 year-old male with a germline 22q11.2 deletion.	Cancer Genet	2014
24634504	Rare variants in TP53 and susceptibility to neuroblastoma.	J Natl Cancer Inst	2014
24008750	Acute renal injury in a 14-year-old with HIV/AIDS and tuberculosis.	Pediatr Infect Dis J	2013
23805968	A 7-year-old boy with abdominal pain, fever, and rash.	Pediatric Annals	2013
22350409	Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.	Cancer Res	2012
21289283	RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.	Proc Natl Acad Sci U S A	2011
21124317	Integrative genomics identifies LMO1 as a neuroblastoma oncogene.	Nature	2011
19412175	Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.	Nat Genet	2009
19536264	Copy number variation at 1q21.1 associated with neuroblastoma.	Nature	2009